HER2-Targeted Therapy Shows Promise across Tumor Types

The antibody–drug conjugate trastuzumab deruxtecan shows promising activity across multiple types of HER2-expressing advanced solid tumors, including traditionally hard-to-treat malignancies, according to data from the DESTINY-PanTumor02 trial. The ongoing study may pave the way for approval of a tumor-agnostic therapy for HER2-expressing and HER2-mutated cancers.